Identification of specific cancer stem cell markers for diagnosis

我们开始了我们的项目，以识别特定的癌症干细胞标记物进行诊断。ES细胞标记物和肿瘤增殖表型标记物用于鉴定CSCs。我们已经报道了PRDM14在临床BC病例中的表达增强。我们还表明，KLF2抑制在乳腺癌和前列腺癌的EZH2肿瘤发生中起重要作用。已知PRDM14和KLF2在ES细胞的维持中起重要作用。根据我们的计划，我们使用细胞分选机收集球状细胞或SP组分，以便从临床癌症组织中获得具有干性表型的癌细胞。之后，我们将这些细胞和正常对照细胞的样本应用于下一代测序仪，以获得候选基因。我们可以获得几个特定的肿瘤干细胞标志物的候选基因，并已经完成了功能分析。现在，我们继续分析临床乳腺癌和胰腺癌组织中特定的癌症干细胞标记物。

We started our project to identfy specific cancer stem cell markers for diagnosis. ES cell markers and phenotypic markers of cancer proliferation are used to identify CSCs. We already have reported that PRDM14 expression is enhanced in clinical BC cases. We also show that KLF2 repression has an important role in EZH2 oncogenesis in breast and prostate cancers. PRDM14 and KLF2 are known to be important for ES cells maintainance. Accoding to our planning, we collected sphere-forming cells or SP fractions using a cell sorter in order to obtain cancer cells with stemness phenotypes from clinical cancer tissues. After that, we applied samples from those cells and normal control cells for a next generation sequencer to obtain the candidate genes. We could obtain several candidate genes for specific cancer stem cell markers and already have finished functional analysis for them. Now, we proceed to analyse clinical breast and pancreatic cancer tissues for specific cancer stem cell markers.